Treatment News : Gilead Reaps $3.48 Billion in Second Quarter Sovaldi Sales

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » July 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


July 23, 2014

Gilead Reaps $3.48 Billion in Second Quarter Sovaldi Sales

With $3.48 billion in sales of the hepatitis C virus (HCV) drug Sovaldi (sofosbuvir), Gilead Sciences reported a second-quarter revenue of $6.53 billion, Reuters reports. The daily pill has also earned Gilead lashings in the press and from hep C advocates for its thousand-dollar-per-day pricing. Sovaldi was approved in December 2013, and by the end of March, it raked in $2.3 billion in first quarter sales, already shattering the record for any new drug’s first year on the market.

According to a statement from John C. Martin, PhD, Gilead’s chairman and chief executive officer, “Sovaldi has been prescribed for more than 80,000 patients in the U.S. and Europe, underscoring the medical community’s recognition of the benefits of this product. We look forward to making Sovaldi available in additional countries.”

$3.03 billion of Sovaldi sales were in the United States, where an estimated 3.5 million people are living with hep C. A 12-week regimen of the therapy costs $84,000, although some people may have to take the drug twice that long, which doubles the cost.

The report made no mention of Gilead’s antiretroviral Truvada (tenofovir/emtricitabine) in terms of its use as pre-exposure prophylaxis (PrEP) against HIV. Gilead has opted not to engage in any kind of direct promotion of the drug for that indication.

Truvada is only approved for use as PrEP in the United States, where it is otherwise a very commonly prescribed treatment for HIV. U.S. sales of the drug increased by 6 percent during the first six months of 2014 when compared with the same period in 2013. This is an increase of nearly $44 million in half-year sales, or the equivalent of about 6,750 people taking the drug, given an approximate $13,000 per year price tag. Because Truvada prescriptions for HIV treatment may have moved in either direction while PrEP prescriptions probably have risen, there is no way to differentiate from these sales figures how many people might be taking PrEP in the United States.

By Gilead’s most recent estimate, 1,774 people filled prescriptions for Truvada as PrEP between January 2011 and March 2013. However, this figure does not represent thousands of people participating in ongoing PrEP research studies who are taking the drug to prevent HIV. Anecdotal evidence suggests that the rate of new PrEP prescriptions has risen significantly during 2014, but there has been no official word from Gilead to support this.

To read the Gilead release, click here.

To read the Reuters article, click here.

Search: Sovaldi, sofosbuvir, Gilead Sciences, second quarter earnings, John C. Martin, Truvada, tenofovir, emtricitabine.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.